The UK pharmaceutical industry trade body, the Association of the British Pharmaceutical Industry (ABPI), have responded to the Prime Minister's speech on the Government's negotiating objectives for exiting the EU.
Theresa May's speech was delivered today (Tuesday 17 January) at Lancaster House, and set out the 12 negotiating priorities for Brexit as part of the Plan for Britain after leaving the EU.
“Today’s announcement is a welcome statement of intent that provides the UK’s pharmaceutical industry with confidence for the future.
The ABPI is pleased that the Prime Minister has identified Britain becoming the best place for science and innovation as one of her twelve negotiation priorities. Our continued leadership in this area will be crucial in creating a truly ‘global Britain’.
The Prime Minister has also said today that the UK’s new relationship with the EU will be set out by the end of the two-year period following the triggering of Article 50. Throughout this period, we will seek to secure the UK’s continued cooperation and alignment with EU rules for the regulation of medicines. This will be the best possible outcome for UK patients.
We look forward to continuing to work with Government to make a success of the UK leaving the EU, securing a deal that builds upon our status as a global pharmaceutical industry leader."
Mike Thompson, ABPI, Chief Executive
### ENDS ###
ABPI Press OfficeEmail: email@example.com to 5pm Monday to Friday: +44 (0) 20 7747 7147 or +44 (0) 20 7747 14415pm to 9am and weekends: +44 (0) 20 7747 1445
About the ABPI
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.
Globally our industry is researching and developing more than 7,000 new medicines.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.